UniQure N.V. (NASDAQ: QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease.
Teva Pharma (TEVA) Reports Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease - read this article along with other careers information, tips and advice on BioSpace
The Huntington Disease Integrated Staging System can help with the early study of the disease and the design of clinical trials for drug safety and efficacy.